martes, 7 de julio de 2020

Immunomedics' breast cancer drug delays tumor growth, prolongs survival

Immunomedics' breast cancer drug delays tumor growth, prolongs survival

Cancer Briefing

STAT Plus: Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial

By ADAM FEUERSTEIN


DAMIAN DOVARGANES/AP
The company secured accelerated approval for the drug, called Trodelvy, to treat women with triple-negative breast cancer.

No hay comentarios:

Publicar un comentario